Clinical trials · Los Angeles, CA
Gastroesophageal Junction clinical trials in Los Angeles
We’re tracking 36 recruiting gastroesophageal junction studies with a site in or near Los Angeles — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Los Angeles
- NCT07488676RecruitingPhase 1/Phase 2
Study of ASP546C for stomach, pancreas, and other cancers
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06901531RecruitingPhase 3
Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Los Angeles, CaliforniaAges 18 years+ - NCT07217704RecruitingPhase 3
New PET scan to find stomach or esophageal cancer spread
This trial tests a new PET scan drug (18F-FAPI) to see if it can better detect where stomach or esophageal cancer has spread. It may help doctors plan the right treatment for you.
Los Angeles, CaliforniaAges 18 years+ - NCT05702229RecruitingPhase 2
Study of combined medicines for advanced stomach cancer with Claudin18.2
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05677490RecruitingPhase 3
Chemo options, with or without nivolumab, for HER2-negative stomach cancer
This Phase 3 trial compares two standard chemotherapy regimens for advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-negative. It also tests whether adding nivolumab (an immune therapy) improves outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Los Angeles, CaliforniaAges 18 years+ - NCT07221149RecruitingPhase 2/Phase 3
Pumitamig vs Nivolumab for untreated stomach or esophagus cancer
This trial compares two treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combination works better.
Los Angeles, CaliforniaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Los Angeles, CaliforniaAges 18 years+ - NCT06445972RecruitingPhase 1/Phase 2
Testing combination therapies for advanced stomach or esophageal cancer
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
Los Angeles, CaliforniaAges 18 years+ - NCT06203600RecruitingPhase 2/Phase 3
Nivolumab plus standard treatment for advanced stomach or esophageal cancer
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Los Angeles, CaliforniaAges 18 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT06469944RecruitingPhase 1/Phase 2
Study of drug combinations for stomach or esophagus cancer
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
Los Angeles, CaliforniaAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Spevatamig for advanced stomach, pancreas, or bile duct cancer
This trial tests a new drug called Spevatamig (PT886), alone or with different chemotherapy and/or immunotherapy combinations, for people with certain advanced stomach, pancreatic, or bile duct cancers. The goal is to see if it shrinks tumors and is safe.
Los Angeles, CaliforniaAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07001748RecruitingPhase 2/Phase 3
Testing abdominal chemo plus standard chemo for stomach cancer spread
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
Los Angeles, CaliforniaAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Burbank, CaliforniaAges 40–75 - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
Santa Monica, CaliforniaAges 18 years+ - NCT06038578RecruitingPhase 2
TRK-950 with standard chemo for advanced stomach cancer
This trial tests a new drug, TRK-950, added to standard chemotherapy (ramucirumab and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after previous treatment. The goal is to see if this combination can help shrink tumors or slow disease progression.
Santa Monica, CaliforniaAges 18 years+
Hear when a new Gastroesophageal Junction trial opens near Los Angeles, CA
We’ll email you when one opens near Los Angeles, CA — at most once a week, no account needed, unsubscribe anytime.
Gastroesophageal Junction trials in other cities
Where these studies are running near Los Angeles
Institutions with a site for the recruiting gastroesophageal junction studies listed above.
- City of Hope Comprehensive Cancer Center · 6 studies
- Cedars-Sinai Medical Center · 4 studies
- University of California, Irvine Medical Center / UC Irvine Health · 4 studies
- University of California, Los Angeles (UCLA) · 4 studies
- USC / Norris Comprehensive Cancer Center · 4 studies
- City of Hope Orange County Lennar Foundation Cancer Center · 2 studies
- Keck Medicine of USC · 2 studies
- Los Angeles General Medical Center · 2 studies
What taking part in a gastroesophageal junction study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting gastroesophageal junction studies in California.
Common questions
- Are there gastroesophageal junction clinical trials near Los Angeles?
- Yes. We're currently tracking 36 recruiting gastroesophageal junction studies with a site near Los Angeles, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a gastroesophageal junction study near Los Angeles?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Los Angeles to take part?
- Not necessarily. These studies have a site near Los Angeles, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a gastroesophageal junction trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New gastroesophageal junction studies open near Los Angeles regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.